AstraZeneca (AZN.L) research
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on researching, developing and commercialising prescription medicines, including treatments across oncology, rare diseases and biopharmaceuticals.
Investment Score
This Investment Score is 64 (Mechanical rating: Hold; Confidence: 83). The composite reflects a mix of clear operating strength — revenue growth, solid margins and strong operating cash flow — offset by liquidity and cash-return questions (zero reported free cash flow, current ratio 1) and weak dividend sustainability. The deterministic factor breakdown driving the 64 score shows bullish Valuation (66), Growth (75) and Profitability (77) contributions, a neutral Financial Health (57) input, and a bearish Dividend Sustainability (25). Analyst consensus is unavailable and excluded.
Score: 64
Dividend evidence
- Ex-dividend 18 February 2027 · £0.80 · estimated · Yahoo
Sources and limitations
Last updated 2 August 2026. Historical payments do not guarantee future distributions. Research and educational information only.